FinancingCompany-reported
What was reported
DURHAM, N.C., June 10, 2026 – Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has commenced an underwritten public offering of its common stock. In addition, Humacyte intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15% of the number of shares of common stock sold in connection with the offering. All of the shares of common stock are being offered by Humacyte.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Jun 11, 2026 · Open the source ↗
What the evidence supports
Humacyte told the SEC (Form 8-K, Item 1.01) that it entered into a financing arrangement or sold its securities. The filing gives Jun 10, 2026 as the date of the earliest event reported. The company also furnished a press release, which is its own account rather than a regulatory statement.
What remains unknown
How much money will actually be raised or drawn, at what final price, and how it will be used beyond what the company stated. Stated amounts can be maximums or targets rather than money already received.
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Press release headlineHumacyte, Inc. Announces Proposed Public Offering of Common StockU.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Jun 11, 2026 · Open the source ↗
Press release lead paragraphDURHAM, N.C., June 10, 2026 – Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has commenced an underwritten public offering of its common stock. In addition, Humacyte intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15% of the number of shares of common stock sold in connection with the offering. All of the shares of common stock are being offered by Humacyte.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Jun 11, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:52 UTC
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.